ERBB2 and breast cancer: For example, the study of Saatci et al. showed that the T-DM1 resistance of HER2-positive breast cancer patients may be overcome by targeting Polo-like kinase 1 (PLK1) through the regulation of CDK1-dependent phosphorylation44.